SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is capturing significant market attention as it prepares for an earnings report that acts as a major bellwether for the entire AI infrastructure sector, with investors intensely debating whether the company can sustain its growth or if it will face a typical post-earnings sell-off. Community discussions are centered on whether the AI trade is peaking, with many traders closely watching for signals on hyperscaler spending, data center demand, and potential competitive pressures to determine if the stock will trigger a broader market move.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently seeing intense community debate as the stock trades near multi-year lows, driven by a mix of heavy skepticism regarding operational performance and optimism fueled by potential tariff relief and AI-powered shopping integrations. While some investors are aggressively shorting the name, others are highlighting insider buying and long-term turnaround potential as reasons to accumulate at these price levels.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust is experiencing intense selling pressure as institutional liquidation and a sharp rise in global bond yields overshadow the metal's long-term industrial demand narrative. While some investors view the volatility as a potential buying opportunity, community sentiment remains deeply divided between those expecting a deeper correction and those betting on a rapid recovery fueled by inflationary risks.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is experiencing significant upward momentum and trending interest as investors anticipate the imminent 80th trial event for its REGAL Phase 3 clinical trial in acute myeloid leukemia. The community is actively discussing a potential short squeeze and institutional accumulation, fueled by optimistic management commentary regarding the immunotherapy platform's curative potential and survival data.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is seeing significant upward momentum as investors rotate back into enterprise software following a series of analyst upgrades and bullish sentiment surrounding the company's AI-driven workflow orchestration capabilities. While some community members remain skeptical of the rapid price swings, many are actively debating whether this is a sustainable recovery or a manipulative rally driven by institutional positioning ahead of broader sector catalysts.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is surging following a strong earnings report that featured a beat on both revenue and earnings, alongside an upward revision of their full-year guidance. The community is actively debating the stock's high valuation relative to its growth, with bulls highlighting the company's rapid expansion and store traffic, while bears express skepticism toward its premium pricing.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following the FDA's acceptance of their supplemental BLA for ANKTIVA, which sets a PDUFA target date of January 6, 2027, to expand treatment options for BCG-unresponsive papillary-only bladder cancer. The community is actively debating the significance of the 10-month regulatory timeline against the urgency of the medical crisis, while highlighting how NCCN Category 2A guideline support is already facilitating patient access.

Gitlawb is a decentralized code collaboration platform designed for AI agents and human developers. It provides a Git-compatible hosting layer where repositories are stored across IPFS, Filecoin, and Arweave, and peer connectivity is handled through libp2p rather than a central server.  Identity on Gitlawb is based on decentralized identifiers (DIDs) using Ed25519 keys. Access control and delegation between users and agents are expressed as UCAN (User Controlled Authorization Networks) capabilities, allowing scoped, revocable permissions to be granted without a central authority. Each identity carries an on-chain trust score derived from verified contributions.  The protocol is accessed through three main surfaces: a Rust node (gitlawb-node) that serves repositories over HTTP and libp2p, a command-line client (gl) that handles identity, repositories, issues, bounties, and UCAN delegation, and a git remote helper (git-remote-gitlawb) that allows standard Git clients to push and pull using gitlawb:// URLs.  Additional products in the ecosystem include MiroClaw, an on-chain prediction market; Gitlawb Spawn, an AI agent orchestration tool; OpenClaude, an open-source agent harness aligned with Playground and Spawn; and a developer playground for testing agent interactions against the protocol.

Gitlawb

Gitlawb is trending as investors rally behind its utility-driven infrastructure and active supply reduction strategies, fueled by speculation regarding strategic partnerships and potential future exchange listings. The community is actively discussing accumulation patterns and the project's long-term economic integration within the AI and crypto space.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant volatility as traders debate whether the stock is undergoing a long-term valuation reset or a brief consolidation period amid broader sector rotation. Sentiment remains polarized, with many investors closely watching the companys enterprise AI and cloud performance while others express frustration over institutional hedging and erratic intraday price action.

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

Lightpath Technologies is attracting significant attention as breakout traders monitor a tightening technical structure and potential supply absorption following institutional selling, while the company's position as a sole-source provider for U.S. Air Force counter-drone systems keeps community sentiment focused on imminent defense contract catalysts. Investors are actively debating the timing of a major NGSRI contract award and the impact of domestic sourcing mandates as the firm continues to expand its infrared imaging and defense-aligned production capabilities.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


CLCD
CoLucid Pharmaceuticals

Feed

News

Sentiment

Fundamentals

Info

Latest CLCD News

CLCDCoLucid Pharmaceuticals